Table 2 Net reclassification improvement analyses between EB and BN2 based on ANN groups
EB | BN2 | |||||
|---|---|---|---|---|---|---|
0 to 0.24 | 0.25 to 0.49 | 0.50 to 0.74 | 0.75 to 1.00 | Total | ||
Metastasis (n = 169): net gain in reclassification proportion = 3.6%, p = 0.38 | 0 to 0.24 | 1 | 3 | 3 | 3 | 10 |
0.6% | 1.8% | 1.8% | 1.8% | |||
0.25 to 0.49 | 2 | 2 | 4 | 5 | 13 | |
1.2% | 1.2% | 2.4% | 3.0% | |||
0.50 to 0.74 | 2 | 1 | 5 | 8 | 16 | |
1.2% | 0.6% | 3.0% | 4.7% | |||
0.75 to 1.00 | 1 | 3 | 11 | 115 | 130 | |
0.6% | 1.8% | 6.5% | 68.0% | |||
Total | 6 | 9 | 23 | 131 | 169 | |
No metastasis (n = 334): net gain in reclassification proportion = −26.0%, p < 0.0001 | 0 to 0.24 | 96 | 31 | 14 | 4 | 145 |
28.7% | 9.3% | 4.2% | 1.2% | |||
0.25 to 0.49 | 41 | 14 | 5 | 2 | 62 | |
12.3% | 4.2% | 1.5% | 0.6% | |||
0.50 to 0.74 | 34 | 19 | 9 | 5 | 67 | |
10.2% | 5.7% | 2.7% | 1.5% | |||
0.75 to 1.00 | 35 | 11 | 8 | 6 | 60 | |
10.5% | 3.3% | 2.4% | 1.8% | |||
Total | 206 | 75 | 36 | 17 | 334 | |